Kamada(NASDAQ) KMDA

Kamada Ltd. is a biopharmaceutical firm specializing in the development, manufacturing, and distribution of protein therapeutics derived from human plasma. The company operates through two main segments: proprietary products and distribution of third-party pharmaceuticals.

Products and Services

• KAMRAB/KEDRAB for rabies prevention
• CYTOGAM for cytomegalovirus disease prevention in transplant recipients
• WINRHO SDF for immune thrombocytopenic purpura treatment

Growth Outlook

• Recent quarterly revenue reached $54.9 million, a significant increase
• Strong demand for proprietary products supports future growth
• Strategic partnerships enhance market reach and product offerings

Financial Highlights

• Trailing twelve months revenue of $206.5 million, reflecting robust performance
• Net income for Q2 2026 was $9.26 million, showcasing profitability
• Current ratio of 4.06 indicates strong liquidity position

Kamada Ltd. has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies that address critical health needs. The company's diverse product portfolio, including treatments for rabies and cytomegalovirus, positions it well for continued growth. Recent financial performance highlights a strong revenue trajectory, with a notable increase in quarterly revenue and net income. The company's solid liquidity, as indicated by a current ratio of 4.06, further supports its operational stability. Strategic partnerships with major pharmaceutical companies enhance Kamada's market presence and product distribution capabilities, paving the way for future expansion. Overall, Kamada Ltd. presents a compelling opportunity within the healthcare sector, driven by its commitment to developing essential therapies and maintaining strong financial health.